Biopharma is experiencing a wave of new capital from private equity, with the influx of investors bringing exciting possibilities to the sector. Biopharmas need to consider how they can capitalise on private equity’s entrance to achieve their strategic goals by positioning themselves as buyers, sellers or competitors to private equity.
Novasecta has explored for MedNous why the biopharma sector is now an attractive area for private equity. In her article Emma explores:
• How private equity firms are entering the market
• How biopharma can maximise the availability of new capital
• How biopharma should position themselves to private equity
The trend of PE entering the market brings our client work into the spotlight where we help clients form strategies that suit their ownership structure and support clients to protect against market changes and address margins.
© 2019 Evernow Publishing Ltd
Reprinted with permission from Mednous July/August 2019 (www.mednous.com)